Literature DB >> 19942947

In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.

Murat Dizbay1, Derya Keten Tozlu, Meltem Yalinay Cirak, Yasemin Isik, Kevser Ozdemir, Dilek Arman.   

Abstract

The emergence of extensive drug-resistant (XDR) Acinetobacter baumannii limits the therapeutic options and leads to high mortality in intensive care units. Combined antibiotic therapy is frequently recommended for the treatment of these infections. Colistin (CO) and tigecycline (TIG), alone or in combination with other antimicrobials, are the most commonly used antibiotics in the treatment of these resistant infections. In this study, the in vitro synergistic activity of TIG and CO were tested for 25 XDR-A. baumannii strains isolated from ventilator-associated pneumonia by the Etest method. Resistance to CO was not detected, whereas 8% of the strains were resistant to TIG. The TIG-CO combination was more synergistic than TIG-rifampin and CO-rifampin according to the fractional inhibitory concentration index. No antagonism was detected between the drugs in the study. There was no strong correlation between the activity of the combinations with reference to strains or genotypes. Our results suggest that the combined use of TIG and CO may be useful for the treatment of XDR-A. baumannii infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942947     DOI: 10.1038/ja.2009.117

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  15 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 2.  Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.

Authors:  P Poulikakos; G S Tansarli; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-16       Impact factor: 3.267

3.  Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.

Authors:  N L Parchem; K A Bauer; C H Cook; J E Mangino; C D Jones; K Porter; C V Murphy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-26       Impact factor: 3.267

4.  Top stories of 2009.

Authors:  S K Todi
Journal:  Indian J Crit Care Med       Date:  2010-01

5.  Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.

Authors:  A Batirel; I I Balkan; O Karabay; C Agalar; S Akalin; O Alici; E Alp; F A Altay; N Altin; F Arslan; T Aslan; N Bekiroglu; S Cesur; A D Celik; M Dogan; B Durdu; F Duygu; A Engin; D O Engin; I Gonen; E Guclu; T Guven; C A Hatipoglu; S Hosoglu; M K Karahocagil; A U Kilic; B Ormen; D Ozdemir; S Ozer; N Oztoprak; N Sezak; V Turhan; N Turker; H Yilmaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-15       Impact factor: 3.267

6.  New Class of Adjuvants Enables Lower Dosing of Colistin Against Acinetobacter baumannii.

Authors:  Bradley M Minrovic; David Jung; Roberta J Melander; Christian Melander
Journal:  ACS Infect Dis       Date:  2018-06-25       Impact factor: 5.084

7.  AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments.

Authors:  Anna C Jacobs; Mitchell G Thompson; Chad C Black; Jennifer L Kessler; Lily P Clark; Christin N McQueary; Hanan Y Gancz; Brendan W Corey; Jay K Moon; Yuanzheng Si; Matthew T Owen; Justin D Hallock; Yoon I Kwak; Amy Summers; Charles Z Li; David A Rasko; William F Penwell; Cary L Honnold; Matthew C Wise; Paige E Waterman; Emil P Lesho; Rena L Stewart; Luis A Actis; Thomas J Palys; David W Craft; Daniel V Zurawski
Journal:  MBio       Date:  2014-05-27       Impact factor: 7.867

Review 8.  Synergistic Effect of Colistin and Rifampin Against Multidrug Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis.

Authors:  Maryam Mohammadi; Hatef Khayat; Koroush Sayehmiri; Setareh Soroush; Fatemeh Sayehmiri; Somayeh Delfani; Lidija Bogdanovic; Morovat Taherikalani
Journal:  Open Microbiol J       Date:  2017-04-28

9.  In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii.

Authors:  Jacinda C Abdul-Mutakabbir; Logan Nguyen; Philip T Maassen; Kyle C Stamper; Razieh Kebriaei; Keith S Kaye; Mariana Castanheira; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

10.  In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.

Authors:  Gyun Cheol Park; Ji Ae Choi; Sook Jin Jang; Seok Hoon Jeong; Choon-Mee Kim; In Sun Choi; Seong Ho Kang; Geon Park; Dae Soo Moon
Journal:  Ann Lab Med       Date:  2016-03       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.